Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.
The aim of our study was to examine compliance with a daily dose of 5 mg alendronate (ALN) and 2.5 mg risedronate (RDN) in actual practice, and to determine the causes of noncompliance through a questionnaire. In addition, we studied the quality of life (QOL) of patients through another disease-related questionnaire. The overall compliance rate remained at approximately 40% one year after the initial dose. The rates did not differ significantly between the ALN group (783 patients) and the RDN group (491 patients). The compliances in the female group and the rheumatism group were better than in the male group and the nonrheumatism group. From the questionnaire, 36% of noncompliant patients showed adverse effects (AEs), and the other noncompliant patients stopped the medication in spite of having no AEs. A logistic regression analysis of factors that might have affected long-term compliance included AEs, an understanding of the disease, the method of ingestion, visiting medical facilities, the shape of the tablet, the cost of the drug, and the explanation of the doctor or pharmacist. This analysis showed that noncompliance occurred mainly due to AEs, the inconvenience of visiting a medical facility, unusual methods of ingestion, and a poor understanding of the disease. According to the results of the questionnaire for QOL assessment, the patients who continued the medication for more than 1 year had improved scores for pain in both the ALN and RDN groups. Osteoporotic treatment needs long-term patient compliance. To improve compliance, it is very important that doctors and pharmacists ensure that patients understand the purpose of this therapy.
Kamatari
Masayuki
M
Maruzen Pharmacy, 3-3-23-104 Nishimikuni, Yodogawa-ku, Osaka 532-0006, Japan. kama89314@yahoo.co.jp
Koto
Shiro
S
Ozawa
Nobuhiro
N
Urao
Chie
C
Suzuki
Yumiko
Y
Akasaka
Eri
E
Yanagimoto
Kae
K
Sakota
Kazumi
K
D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology; D010349:Patient Compliance / Q000706:statistics & numerical data*; D011788:Quality of Life; D000068296:Risedronic Acid; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
D004164:Diphosphonates; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate
Endocr Pract. 2006 Sep-Oct;12(5):522-8
17002926
Osteoporos Int. 2003 Dec;14(12):965-8
14504697
Arch Intern Med. 2005 Nov 14;165(20):2414-9
16287772
Clin Ther. 2002 Nov;24(11):1871-86
12501880
J Bone Miner Metab. 2005;23(2):167-73
15750696
Nurs Clin North Am. 2001 Sep;36(3):433-40, viii
11532658
JAMA. 1999 Aug 18;282(7):637-45
10517716
Yonsei Med J. 2003 Dec 30;44(6):961-7
14703602
South Med J. 2006 Jun;99(6):570-5
16800411
N Engl J Med. 1995 Nov 30;333(22):1437-43
7477143
JAMA. 1999 Oct 13;282(14 ):1344-52
10527181
J Bone Miner Metab. 2004;22(5):469-78
15316868
Pharmacoeconomics. 2002;20(5):289-303
11994039
Mayo Clin Proc. 2006 Aug;81(8):1013-22
16901023
Osteoporos Int. 2004 Dec;15(12):1003-8
15167989
N Engl J Med. 1995 Apr 27;332(17):1125-31
7700285
Osteoporos Int. 2006;17(6):922-8
16609824
Rheum Dis Clin North Am. 2001 Feb;27(1):163-85, vii
11285993
J Pharmacobiodyn. 1981 Nov;4(11):879-85
7328489
Osteoporos Int. 2003 Dec;14(12):1007-12
14557854
Clin Pharmacol Ther. 1995 Sep;58(3):288-98
7554702
Br J Clin Pharmacol. 1999 Oct;48(4):536-42
10583024
Osteoporos Int. 2004 Dec;15(12):975-80
15118812
Maturitas. 2004 Jul 15;48(3):243-51
15207890
Curr Med Res Opin. 2005 Sep;21(9):1453-60
16197664
Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238
16932286
Lancet. 1996 Dec 7;348(9041):1535-41
8950879
Gastroenterology. 2000 Sep;119(3):631-8
10982755
Isr Med Assoc J. 2003 Dec;5(12):859-62
14689753
J Clin Pharm Ther. 1998 Oct;23(5):345-52
9875682
Osteoporos Int. 2000;11(1):83-91
10663363
JAMA. 1998 Dec 23-30;280(24):2077-82
9875874
Osteoporos Int. 2003 May;14(3):259-62
12730745
N Engl J Med. 2001 Feb 1;344(5):333-40
11172164
Pharm Res. 2001 Feb;18(2):166-70
11405286
J Bone Miner Metab. 2004;22(5):462-8
15316867
Aust Fam Physician. 2006 Mar;35(3):135-7
16525527
Am J Med. 2006 Apr;119(4 Suppl 1):S12-7
16563936
Arch Intern Med. 1997 Dec 8-22;157(22):2617-24
9531231
Cancer. 2000 Jan 1;88(1):6-14
10618600
Endocr Rev. 2002 Aug;23(4):570-8
12202472